2024
Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer
McNamara B, Demirkiran C, Hartwich T, Bellone S, Manavella D, Mutlu L, Greenman M, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. Gynecologic Oncology 2024, 183: 133-140. PMID: 38493021, DOI: 10.1016/j.ygyno.2024.01.028.Peer-Reviewed Original ResearchLow grade serous ovarian carcinomaWhole-exome-sequencingGain-of-function mutationsVS-4718Preclinical efficacyLow grade serous ovarian cancerSerous ovarian cancerControl-treated miceTumor growth inhibitionWild-type KRASLoss of heterozygosityDecreased p-ERKRAF/MEK inhibitionMedian survivalOvarian cancerRecurrence rateTherapeutic optionsOral gavageTumor growthTumor samplesIn vivo activityMAPK pathway genesRAF/MEK inhibitorsP-ERKEx vivo
2014
Impact of Body Mass Index on Surgical Outcomes and Analysis of Disease Recurrence for Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging
Menderes G, Azodi M, Clark L, Xu X, Lu L, Ratner E, Schwartz PE, Rutherford TJ, Santin AD, Silasi DA. Impact of Body Mass Index on Surgical Outcomes and Analysis of Disease Recurrence for Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging. International Journal Of Gynecological Cancer 2014, 24: 1118-1125. PMID: 24927247, DOI: 10.1097/igc.0000000000000156.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdultAgedAged, 80 and overBody Mass IndexCarcinosarcomaCystadenocarcinoma, SerousEndometrial NeoplasmsFemaleFollow-Up StudiesHumansHysterectomyLymph Node ExcisionLymphatic MetastasisMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRetrospective StudiesRoboticsSurvival RateConceptsBody mass indexRecurrence-free survivalRobotic-assisted stagingEndometrial cancerRecurrence rateDisease recurrenceMass indexMean postoperative hospitalizationLymph node countMean operative timeLong-term outcomesNonendometrioid cancersMorbid obesityPostoperative hospitalizationMetastatic diseaseNonendometrioid histologyObese patientsOverall survivalConsecutive patientsOperative outcomesHistologic subtypeOperative timeSurgical outcomesEndometrioid carcinomaMean age
2013
Early stage uterine serous carcinoma: Management updates and genomic advances
Fader AN, Santin AD, Gehrig PA. Early stage uterine serous carcinoma: Management updates and genomic advances. Gynecologic Oncology 2013, 129: 244-250. PMID: 23321062, DOI: 10.1016/j.ygyno.2013.01.004.Peer-Reviewed Original ResearchConceptsEarly stage uterine serous carcinomaUterine serous carcinomaRisk of recurrenceResidual uterine diseaseTaxane-based chemotherapyEarly-stage diseaseNumber of patientsCancer-related deathHigh recurrence rateOptimal management approachHER2/neuPotential therapeutic targetAvailable literaturePIK3CA/Adjuvant therapyCervical involvementStage diseaseBiologic therapyProspective trialEndometrial cancerProspective studyRecurrence rateSerous carcinomaSurvival outcomesAggressive subtype
2010
HER-2/NEU overexpression in vulvar Paget disease: the Yale experience
Richter CE, Hui P, Buza N, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. HER-2/NEU overexpression in vulvar Paget disease: the Yale experience. Journal Of Clinical Pathology 2010, 63: 544. PMID: 20418225, DOI: 10.1136/jcp.2010.077446.Peer-Reviewed Original ResearchConceptsVulvar Paget's diseasePaget's diseaseNeu overexpressionOutcome dataHER-2/neu expressionHER-2/neuEfficacy of trastuzumabExtensive reconstructive proceduresHigh recurrence rateMedical record searchInteresting treatment optionSurgical treatmentRecurrence rateTreatment optionsNeu expressionClinical trialsReconstructive proceduresTissue microarrayPatientsRecord searchTumor samplesYale experienceDiseaseNeuStaining results